Passage Bio (NASDAQ:KROS) Stock Rating Lowered by Zacks Investment Research

Passage Bio (NASDAQ:KROS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company’s product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA. “

A number of other research analysts have also weighed in on the stock. Piper Sandler assumed coverage on shares of Passage Bio in a research note on Sunday, May 3rd. They issued an “overweight” rating and a $35.00 price target on the stock. HC Wainwright assumed coverage on shares of Passage Bio in a research note on Monday, May 4th. They issued a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Passage Bio in a research note on Monday, May 4th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, SVB Leerink assumed coverage on shares of Passage Bio in a research note on Monday, May 4th. They issued an “outperform” rating and a $42.00 target price on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Passage Bio has a consensus rating of “Buy” and an average price target of $39.20.

Passage Bio stock traded down $0.01 during midday trading on Thursday, reaching $27.31. The company had a trading volume of 29,480 shares, compared to its average volume of 53,650. Passage Bio has a 12-month low of $19.10 and a 12-month high of $32.75.

Passage Bio Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Recommended Story: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on Passage Bio (KROS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.